I’m writing this from the air.
Seatbelt on. Cabin dim. The kind of quiet that makes your thoughts feel louder than they should be.
Tokyo is ahead of me.
And so is a question I can’t quite put down—not because it’s dramatic, but because it’s precise.
One lesion grew.
Everything else didn’t.
And “stable disease,” it turns out, can be both true and incomplete in the same sentence.
The detail that won’t stay quiet
The research encounter note from my last visit lands with a kind of administrative calm:
- Target lesions: no progression
- Overall assessment: Stable Disease
- Plan: proceed, come back in two weeks
That’s the comfort.
Then the CT report adds the part that doesn’t fit neatly into that comfort:
- The dominant segment 8 liver metastasis (along the resection margin) increased from 2.5 cm to 3.4 cm
- Other liver lesions remain stable
- No definite extrahepatic disease
That’s the precision.
And in my life right now, precision matters more than reassurance.
The email I sent wasn’t emotional; it was procedural
I emailed my clinical trial contact—the person whose job is to keep the protocol clean and the paperwork true—with what felt like a reasonable question:
If one lesion is growing but the overall assessment is stable, can we treat that lesion locally—SBRT, ablation, embolization, or surgery—while continuing the study drug?
Not as an act of panic.
As an act of strategy.
The study drug seems to be helping elsewhere. I’m tolerating it. I’m functioning. Appetite’s good. Labs are fine. I’m still moving through the world like myself.
So if there’s a single outlier—one lesion behaving badly—surely there’s a way to address the outlier without burning the whole plan down.
That was the shape of the question.
The answer was clear, and it changed the frame
The reply came back with a key phrase that carries weight in clinical trial life:
Local treatment of an enlarging non-target lesion must be palliative in nature. If it’s not palliative, it’s not permitted—unless the sponsor approves it, and even then, the protocol language matters.
There was also another point that matters more than most people realize: Just because a lesion isn’t a “target lesion” doesn’t mean it doesn’t count.
Non-target lesions are still tracked. The assessment is qualitative rather than measured like targets, but growth there can still drive a classification of progression.
In other words: You can be “stable” on the target lesion worksheet and still be drifting toward something worse.
The overall classification is the worst of the categories.
That’s the part that lands in your chest.
Because it means the system is not ignoring this lesion.
It’s just not measuring it the way my brain wants it measured.
So what does “palliative” actually mean here?
Palliative is one of those words that changes meaning depending on who’s holding it.
In normal human language, palliative means:
Relieve symptoms. Protect the quality of life. Reduce suffering. Help you function.
In trial language, palliative often means: Allowed only if the treatment is justified by symptoms—or by a clear risk of near-term harm that requires intervention.
And that distinction matters because it creates an uncomfortable tension: If I’m feeling okay, and the lesion isn’t causing obvious symptoms, it may be harder to justify a local treatment as “palliative.”
But if we wait until it causes symptoms, we’re letting the tumour set the timing.
That’s the trap.
A trial is designed to measure a drug.
It’s not designed to accommodate every smart, sensible, real-world move you’d make if measurement purity wasn’t part of the deal.
This is what “stable” looks like when you read the fine print
I’m still struck by how the same scan can produce two different emotional outcomes depending on which sentence you read last.
“Stable disease” can sound like a verdict: You’re okay. It’s working. Keep going.
But in reality, it’s a classification inside a framework. It means: Changes do not meet a defined threshold for progression based on the assessed criteria and categories.
That can be true even when something important is changing.
I’m learning—again—that oncology is full of paradoxes: Reassuring language sitting beside unsettling facts
A category that’s accurate but not complete
A plan that’s reasonable but potentially fragile
And the job, if you want to stay sane, is not to choose comfort or precision.
It’s to hold both and keep asking the next clean question.
The question that decides everything
The trial contact also made it clear that some of this is outside their scope.
Which is fair.
They manage protocol. They protect the integrity of the study. They communicate what’s allowed.
But medical strategy—the thing that actually shapes my next months—belongs to my treating oncologist.
So the next step isn’t arguing with a coordinator.
The next step is to ask my oncologist the questions that actually determine what happens next.
This is the distilled version—the cleanest shape of what I’m asking at my next visit:
- Does the segment 8 growth meet criteria for progression on protocol, including the possibility of progression being called based on non-target lesion progression?
- If it does not meet progression yet, do you recommend continuing on the study as-is, given that one lesion is enlarging?
- Is there any pathway—with sponsor approval—to treat this single lesion locally while remaining on drug, even if framed as symptom-prevention / palliative intent?
- If local treatment for disease control is not permitted on protocol, can we still arrange referral opinions (radiation oncology, interventional radiology, hepatobiliary surgery) to understand feasibility and timing if we need to transition off study?
- Would a liver MRI help for characterization and local treatment planning?
No drama.
No ultimatum.
Just tell me what the rules actually allow, what you recommend clinically, and help me plan the next move with eyes open.
This is what advocacy looks like now
People imagine advocacy as confrontation.
For me, it’s quieter than that.
It’s reading what was written.
Not turning it into what I wish it said.
Not letting “stable” become a sedative.
Advocacy is precision with a steady voice.
It’s asking questions that make it harder for ambiguity to hide.
It’s planning ahead rather than reacting late.
It’s refusing to let a protocol definition become my full understanding of what’s happening in my body.
Why I’m writing this from an airplane
Because this is the odd truth of my life right now: I can be heading to Tokyo and still be thinking about segment 8.
I can be excited about streets and light and the way a city moves—and still be holding a number in my head: 2.5 to 3.4.
I can live.
And I can plan.
And I can insist on clarity.
That’s the new skill set.
Not denial.
Not despair.
Just disciplined attention.
Tokyo is not an escape.
It’s a reminder that my life is still made of things that aren’t medical.
But the medicine is still real.
The lesion is still real.
And the plan needs to be real, too.
The real question underneath the protocol language
When you strip away target lesions, non-target lesions, sponsor approval, palliative intent—what’s left is brutally simple: Is the study drug buying meaningful control overall, with one outlier lesion we can manage?
Or is this the first sign the cancer is adapting, and the dam is starting to crack?
I don’t have that answer yet.
But I’m asking for it directly.
Because I’m done building plans out of partial comfort.
I want the most precise truth available.
Then I’ll decide what belongs next in this story—calmly, clearly, and on purpose.
And for now, the seatbelt light is still on.
Tokyo is still ahead.
And I’m still moving forward—through the air, through uncertainty, through the narrow space between comfort and precision—because that’s what there is to do.